United Therapeutics officer to sell 8,300 shares
UNITED THERAPEUTICS CORPORATION (UTHR) received a notice that officer Paul Mahon intends to sell up to 8,300 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
UNITED THERAPEUTICS CORPORATION (UTHR) received a notice that officer Paul Mahon intends to sell up to 8,300 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The planned sale has an aggregate market value of $4,000,836.55 and relates to shares acquired via a stock option exercise on September 3, 2026.
The notice states that 42,890,692 shares of United Therapeutics common stock are outstanding, and lists several prior Rule 144 sales by Mahon over the past three months, each involving 8,300 shares on various dates in June, July, and August 2026.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
Securities To Be Sold regulatory
Securities Sold During The Past 3 Months regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing for UTHR disclose about Paul Mahon?
What past UTHR stock sales by Paul Mahon are disclosed?
What is the role of Morgan Stanley Smith Barney LLC in this UTHR Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.